Mahmud et al. suggested the possible use of the tyrosine kinase inhibitor erlotinib in a subset of adult AML patients that had high epidermal growth factor receptor (EGFR) and EGFR phosphorylation levels relative to normal CD34+ cells measured by RPPA. Here, EGFR is linked to acute myeloid leukemia.